Hepatic Tumor Pipeline Analysis Report 2025

Hepatic tumors are primary malignant liver cancers and a leading cause of cancer-related mortality. According to Walaa Abdelhamed et al., hepatocellular carcinoma (HCC) is the sixth most diagnosed cancer, with 906,000 new cases, and the third leading cause of cancer deaths globally, accounting for 830,000 deaths in 2020. Therapies include surgical resection, liver transplantation, locoregional treatments, and systemic therapies. According to the hepatic tumor pipeline analysis by Expert Market Research, growing focus on precision medicine, immunotherapy, and innovative drug development is expected to drive significant growth in the treatment landscape in the coming years.

Report Coverage

The Hepatic Tumor Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hepatic tumor therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hepatic tumor. The hepatic tumor report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hepatic tumor pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hepatic tumor treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hepatic tumor.

Hepatic Tumor Pipeline Outlook

Hepatic tumor is a malignant growth in the liver, often arising from chronic liver diseases, viral infections such as hepatitis B or C, cirrhosis, or genetic mutations. Tumor cells proliferate uncontrollably, impairing liver function and potentially spreading to other organs. Early detection is essential for improved patient outcomes.

Hepatic tumor treatments include surgical resection, liver transplantation, targeted therapies, immunotherapy, and chemotherapy to control tumor growth, reduce metastasis, and enhance survival. For example, in May 2025, Galmed Pharmaceuticals’ Aramchol markedly boosted Bayer’s Regorafenib efficacy, significantly reducing hepatic tumor growth in preclinical models by enhancing autophagy and tumor cell death. A Phase 1b trial is scheduled for Q4 2025.

Hepatic Tumor Epidemiology

According to Walaa Abdelhamed et al., hepatocellular carcinoma (HCC), the most common malignant hepatic tumor, accounted for 906,000 new cases and 830,000 deaths globally in 2020. HCC represents approximately 90% of primary liver cancers. Patients with liver cirrhosis, particularly those with hepatitis B or C infections, show significantly higher incidence, with yearly and five-year cumulative rates of 1%-4% and 5%-30%, respectively. Hepatitis B remains the leading risk factor, causing nearly 50% of cases. The ongoing advancements in the HCC drug pipeline aim to improve survival outcomes and provide targeted, effective therapies for high-risk patient populations.

Hepatic Tumor - Pipeline Therapeutic Assessment

This section of the report covers the analysis of hepatic tumor drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The hepatic tumor pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Polymers

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Hepatic Tumor Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 51%, covers a major share of the total hepatic tumor clinical trials. It is followed by phase I at 30%, and phase III at 13%. This distribution indicates a strong focus on drug development and optimization, with substantial investments in early and mid-stage trials. Such segmentation enhances the likelihood of introducing effective therapies to the market, potentially improving patient outcomes and advancing treatment options for hepatic tumors.

Hepatic Tumor Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the hepatic tumor pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The hepatic tumor report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hepatic tumors. Immune checkpoint inhibitors are emerging as a promising drug class in the hepatic tumor pipeline. For example, Henlius’ HLX13, an anti-CTLA-4 fully human monoclonal antibody biosimilar of ipilimumab, entered a Phase 1/3 clinical trial in May 2025. HLX13 is being evaluated for unresectable advanced hepatocellular carcinoma in combination with nivolumab, aiming to enhance T-cell-mediated tumor cell death and improve patient outcomes.

Hepatic Tumor Clinical Trials - Key Players

The report for the hepatic tumor pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hepatic tumor therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hepatic tumor clinical trials:

• Tempest Therapeutics
• TriSalus Life Sciences, Inc.
• Captor Therapeutics S.A.
• Qilu Pharmaceutical Co., Ltd.
• Shanghai Henlius Biotech
• Tvardi Therapeutics, Incorporated
• Hoffmann-La Roche
• METiS Pharmaceuticals
• Etnova Therapeutics Corp.
• Chugai Pharmaceutical
• Tyra Biosciences, Inc.
• Chiome Bioscience Inc.
• SEED Therapeutics, Inc.

Hepatic Tumor - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hepatic tumor. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hepatic tumor drug candidates.

Drug: TPST-1120

Tempest Therapeutics is developing TPST-1120 as a potent competitive antagonist of PPARα, inhibiting fatty acid oxidation and promoting immune activation. This Phase 3, randomized, double-blind study is examining the efficacy and safety of TPST-1120 in combination with atezolizumab and bevacizumab in adults with unresectable or metastatic hepatocellular carcinoma (HCC) not previously treated with systemic therapy. The trial is measuring overall survival, progression-free survival, and tumor response while assessing tolerability and immune-related effects.

Drug: SD-101

SD-101 is an investigational TLR9 agonist sponsored by TriSalus Life Sciences, Inc., currently being studied in an open-label, Phase 1b/2 trial for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The study is examining the safety, tolerability, and optimal dose of SD-101 delivered via Pressure-Enabled Drug Delivery (PEDD) alone or combined with checkpoint inhibitors, including pembrolizumab, nivolumab, or ipilimumab. The trial is evaluating immune activation and tumor response while advancing innovative regional immuno-oncology therapy.

Drug: CT-01

CT-01 is an investigational drug sponsored by Captor Therapeutics S.A., currently under a Phase 1, open-label, multicenter study in subjects with intermediate or advanced hepatocellular carcinoma (HCC). The study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of CT-01 as monotherapy and in combination with everolimus. CT-01 employs targeted protein degradation technology, removing GSPT1 to trigger apoptosis and NEK7 to inhibit tumor-promoting inflammation, aiming to suppress tumor growth and induce regression.

Key Questions Answered in the Hepatic Tumor Pipeline Insight Report

• Which companies/institutions are leading the hepatic tumor drug development?
• Which company is leading the hepatic tumor pipeline development activities?
• What is the current hepatic tumor commercial assessment?
• What are the opportunities and challenges present in the hepatic tumor pipeline landscape?
• What is the efficacy and safety profile of hepatic tumor pipeline drugs?
• Which company is conducting major trials for hepatic tumor drugs?
• Which companies/institutions are involved in hepatic tumor collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in hepatic tumor?

Reasons To Buy This Report

The Hepatic Tumor Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hepatic tumor. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hepatic tumor collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.